Intra-Cellular Therapies, Inc.
ITCINASDAQHealthcare
$131.87
+$0.00(+0.00%)
Market Cap$14.0B
P/E Ratio—
52W High$131.98
52W Low$64.09
Intra-Cellular Therapies, Inc. (ITCI) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ITCI · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2025Report Date: Feb 21, 2025EPS Actual
-$0.16
Est. -$0.08 · -100.0%
Revenue
$0.20B
Est. $0.19B · +3.0%
Fiscal Period
Q1 FY2025
FY ends December
Report Date
Feb 21, 2025
After Market Close
▼ Miss EPS▲ Beat Revenue
ITCI reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $6.21B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$6.21B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q1 FY2025 | Feb 21, 2025 | -$0.08 | -$0.16 | -100.0% | $0.20B | $0.19B | +3.0% |
| ▼ Q4 FY2024 | Oct 30, 2024 | -$0.18 | -$0.25 | -38.9% | $0.18B | $0.19B | -9.7% |
| ▲ Q3 FY2024 | Aug 7, 2024 | -$0.18 | -$0.16 | +11.1% | $0.16B | $0.16B | +2.2% |
| ▲ Q2 FY2024 | May 7, 2024 | -$0.31 | -$0.16 | +48.4% | $0.14B | $0.14B | +2.5% |
| ▲ Q1 FY2024 | Feb 22, 2024 | -$0.44 | -$0.30 | +31.8% | $0.13B | $0.14B | -3.1% |
| ▲ Q4 FY2023 | Nov 2, 2023 | -$0.59 | -$0.25 | +57.6% | $0.13B | $0.14B | -8.1% |
| ▲ Q3 FY2023 | Aug 3, 2023 | -$0.62 | -$0.45 | +27.4% | $0.11B | $0.11B | +3.3% |
| ▲ Q2 FY2023 | May 4, 2023 | -$0.63 | -$0.46 | +27.0% | $0.09B | $0.09B | +3.0% |
Q1 FY2025
Feb 21, 2025Miss
EPS Actual
-$0.16
EPS Est.
-$0.08
EPS Surpr.
-100.0%
Revenue
$0.20B
Q4 FY2024
Oct 30, 2024Miss
EPS Actual
-$0.25
EPS Est.
-$0.18
EPS Surpr.
-38.9%
Revenue
$0.18B
Q3 FY2024
Aug 7, 2024Beat
EPS Actual
-$0.16
EPS Est.
-$0.18
EPS Surpr.
+11.1%
Revenue
$0.16B
Q2 FY2024
May 7, 2024Beat
EPS Actual
-$0.16
EPS Est.
-$0.31
EPS Surpr.
+48.4%
Revenue
$0.14B
Q1 FY2024
Feb 22, 2024Beat
EPS Actual
-$0.30
EPS Est.
-$0.44
EPS Surpr.
+31.8%
Revenue
$0.13B
Q4 FY2023
Nov 2, 2023Beat
EPS Actual
-$0.25
EPS Est.
-$0.59
EPS Surpr.
+57.6%
Revenue
$0.13B
Q3 FY2023
Aug 3, 2023Beat
EPS Actual
-$0.45
EPS Est.
-$0.62
EPS Surpr.
+27.4%
Revenue
$0.11B
Q2 FY2023
May 4, 2023Beat
EPS Actual
-$0.46
EPS Est.
-$0.63
EPS Surpr.
+27.0%
Revenue
$0.09B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.27 | $0.27 | $0.27 | 3 |
| Q3 FY2025 | $0.10 | $0.10 | $0.10 | 2 |
| Q2 FY2025 | $-0.22 | $0.05 | $0.35 | 4 |
| Q1 FY2025 | $-0.15 | $-0.08 | $0.03 | 4 |
| Q4 FY2024 | $-0.24 | $-0.07 | $0.32 | 9 |
| Q3 FY2024 | $-0.25 | $-0.18 | $-0.09 | 11 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.3B | $0.3B | $0.3B | 1 |
| Q3 FY2025 | $0.2B | $0.2B | $0.2B | 1 |
| Q2 FY2025 | $0.2B | $0.2B | $0.2B | 3 |
| Q1 FY2025 | $0.2B | $0.2B | $0.2B | 3 |
| Q4 FY2024 | $0.2B | $0.2B | $0.2B | 9 |
| Q3 FY2024 | $0.2B | $0.2B | $0.2B | 9 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2025 | Feb 21, 2025 | -100.0% | $128.54 | $128.60 | +0.05% |
| ▼ Q4 FY2024 | Oct 30, 2024 | -38.9% | $76.75 | $85.47 | +11.36% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +11.1% | $78.17 | $73.63 | -5.81% |
| ▲ Q2 FY2024 | May 7, 2024 | +48.4% | $71.01 | $71.21 | +0.28% |
| ▲ Q1 FY2024 | Feb 22, 2024 | +31.8% | $73.28 | $71.93 | -1.84% |
| ▲ Q4 FY2023 | Nov 2, 2023 | +57.6% | $50.87 | $52.38 | +2.97% |
| ▲ Q3 FY2023 | Aug 3, 2023 | +27.4% | $60.87 | $58.89 | -3.25% |
| ▲ Q2 FY2023 | May 4, 2023 | +27.0% | $63.25 | $61.97 | -2.02% |
Q1 FY2025+0.05%
Report Date
Feb 21, 2025
EPS Beat/Miss
-100.0%
Price Before
$128.54
Price After
$128.60
Q4 FY2024+11.36%
Report Date
Oct 30, 2024
EPS Beat/Miss
-38.9%
Price Before
$76.75
Price After
$85.47
Q3 FY2024-5.81%
Report Date
Aug 7, 2024
EPS Beat/Miss
+11.1%
Price Before
$78.17
Price After
$73.63
Q2 FY2024+0.28%
Report Date
May 7, 2024
EPS Beat/Miss
+48.4%
Price Before
$71.01
Price After
$71.21
Q1 FY2024-1.84%
Report Date
Feb 22, 2024
EPS Beat/Miss
+31.8%
Price Before
$73.28
Price After
$71.93
Q4 FY2023+2.97%
Report Date
Nov 2, 2023
EPS Beat/Miss
+57.6%
Price Before
$50.87
Price After
$52.38
Q3 FY2023-3.25%
Report Date
Aug 3, 2023
EPS Beat/Miss
+27.4%
Price Before
$60.87
Price After
$58.89
Q2 FY2023-2.02%
Report Date
May 4, 2023
EPS Beat/Miss
+27.0%
Price Before
$63.25
Price After
$61.97
Avg Beat Reaction-1.61%
Avg Miss Reaction+5.71%
Beat Rate6 / 8 quarters
Largest Move+11.36% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ITCI ends December
Intra-Cellular Therapies, Inc. (ITCI) most recently reported earnings on February 21, 2025 for Q1 FY2025, posting EPS of $-0.16 — missing the analyst consensus of $-0.08 by -100.0%. The next ITCI earnings date is expected around September 1, 2026.
Each quarter, investors track ITCI earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ITCI revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ITCI's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ITCI earnings · 5 questionsIntra-Cellular Therapies, Inc.'s next earnings report is expected around September 1, 2026. ITCI typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ITCI historically reports after market close (AMC).
ITCI earnings datewhen is ITCI earningsITCI next earnings datewhen does ITCI report earningsITCI earnings calendar
▸ Source: FMP · Intra-Cellular Therapies, Inc. SEC filings · US GAAP · Intra-Cellular Therapies, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026